"I am glad that taking part in a trial might help others on their own cancer journey.”
A study using GSK2857916 for people with myeloma and lymphoma
This study is for people with myeloma or lymphoma that has come back after standard treatment or has not responded to treatment.
More about this trial
GSK2857916 is a monoclonal antibody. It is designed to work on a protein found on myeloma and some lymphoma cells. This protein is called B-cell Maturation Antigen (BCMA). GSK2857916 attaches to the BCMA receptors on the myeloma or lymphoma cells and kills them.
Researchers think most people with myeloma have BCMA on the surface of their cells. They think it is also found on the cells of the some types of non Hodgkin lymphoma- diffuse large B cell lymphoma (DLBCL) and follicular lymphoma.
The doctors will need to test a sample of your lymphoma to look for BCMA if you have either of these types.
This study is in 2 parts. In the first part of the study the doctors wanted to find the best dose and how often to have GSK2857916 (the schedule).This part has now closed and part 2 of the study is now open.
The main aims of the study are to:
- find the best dose and how often to have GSK2857916
- learn more about how the drug works in the body
- learn about the side effects of GSK2857916
- see if it is a useful treatment
Who can enter
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
You may be able to join part 2 of this study if all of the following apply.
- You are at least 18 years old
- You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- You have satisfactory blood results
- You are willing to use reliable contraception during the time you have treatment and for 2 months after if there is any possibility you or your partner could become pregnant
If you have myeloma all of the following must apply.
- You have had a stem cell transplant using your own stem cells or are not able to have a transplant. If you have had a stem cell transplant this must have been more than 100 days before starting this study and you must have no infection which needs treatment
- You have had treatment with at least 3 different types of drugs used to treat myeloma
- Your myeloma got worse within 2 months of you finishing your last treatment
- Your doctors are able to review your levels of myeloma through blood or urine tests or, if you have a
plasmacytomathat has been confirmed by a biopsy, you can have CT scans.
If you have lymphoma you must have either diffuse large B cell lymphoma (DLBCL) or follicular lymphoma and you have BCMA on the surface of your lymphoma cells. Also for:
- Diffuse B cell lymphoma- you must have had at least 2 previous treatments that reached your whole body (systemic treatment). At least one of these must have included an anti-CD20 drug such as rituximab. You must have also had a stem cell transplant using your own stem cells or are not able to have a transplant. If you have had a stem cell transplant this must have been more than 100 days before starting this study and you must have no infection which needs treatment
- Follicular lymphoma- you must have had at least 2 previous treatments that reached your whole body (systemic treatment)
You cannot join this study if any of these apply. You
- Have had any treatment for your myeloma or lymphoma 14 days before starting the study treatment
- Have had plasmapheresis (the removal of excess protein from your blood) 7 days before starting the study treatment
- Have had an experimental cancer drug in the last 14 days (or have no traces of the drug in your body) before starting the study treatment
- Have had a monoclonal antibody in the month before starting the study treatment
- Have had a stem cell transplant using stem cells from a donor (an allogeneic transplant)
- Have had major surgery in the last 4 weeks
- Have any serious side effects from previous treatment apart from hair loss and mild tingling and numbness in your fingers and toes (neuropathy)
- Have problems with your heart such as a problem with the rhythm of your heart, angina not controlled by medication, you have had a heart attack, or you have had certain heart procedures such as angioplasty in the 6 months before starting the study
- Have significant heart failure
- Have high blood pressure not controlled by medication
- Have a permanent pacemaker or intra cardiac defibrillator
- Have had any problems with bleeding
- Have a kidney condition that requires treatment such as dialysis
- Have a liver or biliary disease that is causing symptoms and needs treatment
- Have or have had any disease that has affected your cornea (the outer layer of your eye) such as a corneal ulcer
- Have a disease that affects you whole body and this disease is severe or not controlled by medication
- Have an infection that needs treating with antibiotics
- Have HIV
- Have hepatitis B or hepatitis C
- Are sensitive or allergic to any drugs similar to GSK2857916
- Have any other serious medical condition or mental health problem that the study team think could affect you taking part
- Are pregnant or breastfeeding
You might be able to take part if you have another type of cancer as long as:
- this cancer is not affecting your myeloma or lymphoma
- you are not having any treatment apart from hormone therapy
- your cancer has been stable for at least 2 years
This is a phase 1 international study that is in 2 parts. Researchers hope up to 14 people in the UK will join part 1 and 2. Part 1 has now closed.
Everyone in part 2 has the best dose of GSK2857916 found in part 1.
You have GSK2857916 once every 3 weeks.
Every 3 week period is called a cycle of treatment. You have up to 16 cycles as long as you don’t have any severe side effects and the drug is helping you.
You have GSK2857916 as a drip into your vein. It takes about an hour.
Samples for research
As well as some routine blood tests to check your general health you have some extra blood tests. These are to look at how the drug is working in your body. This is called
The blood samples may also be used to look for
You’ll see the doctors and have some tests before you start treatment. The tests might include
- A physical examination
- Blood tests
- Urine test
- Heart trace (
- Heart scan (
- Eye examination
- Chest X-ray
- Bone marrow test
- A sample of your bone (bone biopsy)
- CT scan if you have lymphoma
You may also need a CT scan to check if you any myeloma outside of your bone marrow.
You go to hospital for your treatment. You might need to stay overnight. The study team will explain how often they need to see you.
During the time you are having treatment you have regular
- Examinations by the doctor
- Blood tests
- Urine tests
You also have steroid eye drops on the day you have treatment and for 3 days afterwards.
You have CT scans and bone marrow tests at different points during treatment. These check your myeloma or lymphoma and how the GSK2857916 is working.
3 months after you have completed treatment someone from the study team will telephone to see how you are.
As this is the first time people have had GSK2857916 there may be some unknown side effects.
Your doctors closely monitor you during the time you are in hospital. They will give you a number for the hospital when your return home. Contact the hospital straightaway if you are worried about anything once you have gone home.
The possible side effects of GSK2857916 include
- a reaction when the drug is given, this can include high temperature (fever), chills, low blood pressure, a fast pulse, cough, back or tummy pain, feeling or being sick, diarrhoea, itching, rash, shortness of breath and problems breathing
- decrease in the amount of urine you pass
- dry and itchy eyes
- blurred vision
- high temperature (fever)
- difficulty breathing
The study doctors will explain all the possible side effects to you before you join the study.
How to join a clinical trial
Professor Kwee Yong
Experimental Cancer Medicine Centre (ECMC)